
Olatec: A NY-based biopharmaceutical firm developing oral therapeutics for a range of inflammatory diseases.
Founded in New York, Olatec Therapeutics is a privately held biopharmaceutical company committed to developing safe, oral NLRP3 antagonist therapeutics. Their core mission is to treat and prevent a wide array of acute and chronic inflammatory diseases mediated by Interleukin-1 (IL-1), such as arthritis, heart failure, and asthma. Olatec's vision is to revolutionize the treatment landscape for these conditions through innovative, patient-centric solutions.
Olatec has garnered attention from notable investors and has assembled a distinguished team of experts in biopharmaceuticals. The company's key achievements include advancing their lead compound through various stages of clinical trials, demonstrating significant potential in addressing unmet medical needs. Olatec's impact lies in its pioneering approach to inflammation management, promising improved quality of life for patients worldwide.

Ocelot Bio
ocelotbio.com

Logical Therapeutics

Halia Therapeutics

Osprey Pharmaceuticals USA
ospreypharma.com

13 Therapeutics

InflammX Therapeutics
inflammx.com

Siolta Therapeutics

Arete Therapeutics

Landos Biopharma

Oligomerix
oligomerix.com

Forward Therapeutics
forward-tx.com

Thelium Therapeutics

Aristea Therapeutics

Exalys Therapeutics

Spyre Therapeutics
aeglea.com
Companies similar to Olatec Therapeutics include Ocelot Bio, Logical Therapeutics, Halia Therapeutics and Osprey Pharmaceuticals USA.
Olatec Therapeutics was founded in 2003.
Olatec Therapeutics' headquarters is located in New York City, NY, US.
As of Mar 10, 2023, Olatec Therapeutics has raised a total of $102.3M (USD).
Olatec Therapeutics has 14 employees as of Feb 4, 2024.